Ensuring Patient Access to Critical Breakthrough Products Act of 2025
Summary
SB1717, titled the Ensuring Patient Access to Critical Breakthrough Products Act of 2025, would change Medicare coverage rules for certain medical devices that receive a federal “breakthrough device” designation. The bill creates a new Medicare framework under which qualifying devices would receive a four-year transitional coverage period beginning on the date of designation, during which Medicare coverage would be protected from denial under specified circumstances. It also directs the Secretary of Health and Human Services to establish a process for designating eligible devices, including manufacturer application, a six-month decision deadline, and annual reporting to Congress.
The bill further requires Medicare to make a final national coverage determination for a breakthrough device before the end of the transitional coverage period, provided the request was submitted early enough in that period. It also appropriates $10 million annually from fiscal years 2026 through 2031 to CMS to implement the new requirements. In effect, the bill would accelerate and standardize Medicare coverage review for newly designated breakthrough devices and create a temporary coverage pathway while longer-term coverage decisions are pending.
Impact
The bill would amend Title XVIII of the Social Security Act by adding a new Medicare coverage exception, defining “breakthrough device” and “transitional coverage period,” and creating a new section governing designation of such devices. It would also modify the national coverage determination process to ensure timely final decisions for these devices and provide dedicated CMS funding to administer the program. The practical effect would be to expand and speed Medicare access for certain FDA-designated medical devices, while preserving limited authority to deny coverage for non-label use or where clinical review shows undue risk of harm.
Sentiment
The available context shows no recorded committee debate or votes, so there is no documented opposition or support from hearings or roll call history. Based on the bill’s purpose and structure, the measure appears designed to improve patient access and reduce delays in Medicare coverage for innovative devices, suggesting a generally pro-innovation and pro-access orientation. The absence of transcripts or votes means sentiment cannot be measured directly, but the bill’s sponsors and framing indicate a favorable policy intent toward faster coverage of breakthrough technologies.
Contention
The main potential points of contention are likely to be the balance between faster access and Medicare program safeguards. Supporters would likely emphasize earlier patient access to innovative devices and a clearer, time-bound coverage process, while critics may question whether the bill could pressure Medicare to cover devices before full evidence is available or increase program costs. Another possible issue is the scope of the new designation process, including whether the Secretary’s criteria and timelines are sufficiently rigorous and whether the $10 million annual appropriation is adequate to implement the new responsibilities.